Sequenom Shares Plunged: What You Need to Know

Before you go, we thought you'd like these...
Before you go close icon

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of genomic science expert Sequenom (NAS: SQNM) fell as far as 11.7% this morning on very heavy volume.

So what: Last night's second-quarter report was somewhat disappointing, missing the Street's earnings targets by 23% despite cutting losses dramatically year over year. Management said that the quarter met internal goals of "continued revenue growth and effective cost controls," but that wasn't good enough for grumpy investors.

Now what: One shudders to think what might have happened to Sequenom if analysts were critical of the results! Two firms reiterated their existing stances of one buy and one hold. By contrast, sector rival Pacific Biosciences of California (NAS: PACB) blew out expectations but received a downgrade for its efforts, and those shares are down by 31% at the moment. I look at these incongruous market reactions and think "buying opportunity," though I'd be very careful about backing up the truck when Mr. Market so clearly needs to start taking his meds.

Interested in more info on Sequenom? Add it to your watchlist.

At the time this article was published Fool contributor Anders Bylund holds no position in any of the companies discussed here. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool is investors writing for investors.

Copyright © 1995 - 2011 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners